Cargando…

A20 Haploinsufficiency in East Asia

A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Tomonori, Kadowaki, Saori, Ohnishi, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664410/
https://www.ncbi.nlm.nih.gov/pubmed/34899744
http://dx.doi.org/10.3389/fimmu.2021.780689
_version_ 1784613841418584064
author Kadowaki, Tomonori
Kadowaki, Saori
Ohnishi, Hidenori
author_facet Kadowaki, Tomonori
Kadowaki, Saori
Ohnishi, Hidenori
author_sort Kadowaki, Tomonori
collection PubMed
description A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembling Behçet’s disease (BD). In addition to autoinflammatory symptoms, HA20 was also reported to be associated with autoimmune diseases and immunodeficiency. Because the phenotypes associated with HA20 are broad, with different severities observed even among individuals in the same family with identical mutations, it has been assumed that the symptoms of HA20 may depend on genetic background and environmental factors. In this review, we summarize the characteristics of patients with HA20 in East Asia and compare these with patients in other regions, mainly the USA and Europe. Patients with HA20 in East Asia developed recurrent fever more frequently than patients in other regions, but were less likely to develop typical BD symptoms such as skin rashes and genital ulcers. In addition, patients with HA20 in East Asia had low rates of complication with autoimmune diseases and low autoantibody detection rates. While anti-TNF-α agents were the primary treatments for severe HA20 in East Asia, anti-interleukin-1 agents and Janus kinase inhibitors were also administered in other regions. Future studies will need to establish methods for analyzing the pathophysiology of HA20 and determining optimal treatment strategies for each patient.
format Online
Article
Text
id pubmed-8664410
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86644102021-12-11 A20 Haploinsufficiency in East Asia Kadowaki, Tomonori Kadowaki, Saori Ohnishi, Hidenori Front Immunol Immunology A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembling Behçet’s disease (BD). In addition to autoinflammatory symptoms, HA20 was also reported to be associated with autoimmune diseases and immunodeficiency. Because the phenotypes associated with HA20 are broad, with different severities observed even among individuals in the same family with identical mutations, it has been assumed that the symptoms of HA20 may depend on genetic background and environmental factors. In this review, we summarize the characteristics of patients with HA20 in East Asia and compare these with patients in other regions, mainly the USA and Europe. Patients with HA20 in East Asia developed recurrent fever more frequently than patients in other regions, but were less likely to develop typical BD symptoms such as skin rashes and genital ulcers. In addition, patients with HA20 in East Asia had low rates of complication with autoimmune diseases and low autoantibody detection rates. While anti-TNF-α agents were the primary treatments for severe HA20 in East Asia, anti-interleukin-1 agents and Janus kinase inhibitors were also administered in other regions. Future studies will need to establish methods for analyzing the pathophysiology of HA20 and determining optimal treatment strategies for each patient. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8664410/ /pubmed/34899744 http://dx.doi.org/10.3389/fimmu.2021.780689 Text en Copyright © 2021 Kadowaki, Kadowaki and Ohnishi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kadowaki, Tomonori
Kadowaki, Saori
Ohnishi, Hidenori
A20 Haploinsufficiency in East Asia
title A20 Haploinsufficiency in East Asia
title_full A20 Haploinsufficiency in East Asia
title_fullStr A20 Haploinsufficiency in East Asia
title_full_unstemmed A20 Haploinsufficiency in East Asia
title_short A20 Haploinsufficiency in East Asia
title_sort a20 haploinsufficiency in east asia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664410/
https://www.ncbi.nlm.nih.gov/pubmed/34899744
http://dx.doi.org/10.3389/fimmu.2021.780689
work_keys_str_mv AT kadowakitomonori a20haploinsufficiencyineastasia
AT kadowakisaori a20haploinsufficiencyineastasia
AT ohnishihidenori a20haploinsufficiencyineastasia